These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 11159545

  • 1. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
    Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G.
    Blood; 2001 Feb 15; 97(4):1115-22. PubMed ID: 11159545
    [Abstract] [Full Text] [Related]

  • 2. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
    Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C.
    J Lab Clin Med; 2001 Aug 15; 138(2):130-8. PubMed ID: 11477380
    [Abstract] [Full Text] [Related]

  • 3. IRC011, a new synthetic chelator with selective interaction with catabolic red blood cell iron: evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture.
    Rivkin G, Link G, Simhon E, Cyjon RL, Klein JY, Hershko C.
    Blood; 1997 Nov 15; 90(10):4180-7. PubMed ID: 9354689
    [Abstract] [Full Text] [Related]

  • 4. ICL670A: preclinical profile.
    Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, Sergejew T, Hauffe S, Thomas H, Schnebli HP.
    Adv Exp Med Biol; 2002 Nov 15; 509():185-203. PubMed ID: 12572995
    [No Abstract] [Full Text] [Related]

  • 5. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores.
    Zevin S, Link G, Grady RW, Hider RC, Peter HH, Hershko C.
    Blood; 1992 Jan 01; 79(1):248-53. PubMed ID: 1728313
    [Abstract] [Full Text] [Related]

  • 6. Current status of iron overload and chelation with deferasirox.
    Choudhry VP, Naithani R.
    Indian J Pediatr; 2007 Aug 01; 74(8):759-64. PubMed ID: 17785900
    [Abstract] [Full Text] [Related]

  • 7. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Aug 01; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 8. Development of tridentate iron chelators: from desferrithiocin to ICL670.
    Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J, Alberti D.
    Curr Med Chem; 2003 Jun 01; 10(12):1065-76. PubMed ID: 12678677
    [Abstract] [Full Text] [Related]

  • 9. Deferasirox pharmacokinetics in patients with adequate versus inadequate response.
    Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK, Grant FD, Paley C, Shannon M, Neufeld EJ.
    Blood; 2009 Nov 05; 114(19):4009-13. PubMed ID: 19724055
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B, study CICL670A2201 investigators.
    Am J Hematol; 2013 Dec 05; 88(12):1068-73. PubMed ID: 23946212
    [Abstract] [Full Text] [Related]

  • 11. Do we need more iron-chelating drugs?
    Kontoghiorghes GJ.
    Lancet; 2003 Aug 09; 362(9382):495-6. PubMed ID: 12927446
    [No Abstract] [Full Text] [Related]

  • 12. Deferasirox : a review of its use in the management of transfusional chronic iron overload.
    Yang LP, Keam SJ, Keating GM.
    Drugs; 2007 Aug 09; 67(15):2211-30. PubMed ID: 17927285
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F, Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S, Porter JB.
    Drug Metab Dispos; 2010 May 09; 38(5):808-16. PubMed ID: 20097723
    [Abstract] [Full Text] [Related]

  • 14. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
    Link G, Ponka P, Konijn AM, Breuer W, Cabantchik ZI, Hershko C.
    Blood; 2003 May 15; 101(10):4172-9. PubMed ID: 12511418
    [Abstract] [Full Text] [Related]

  • 15. Assessment of antimalarial effect of ICL670A on in vitro cultures of Plasmodium falciparum.
    Goudeau C, Loyevsky M, Kassim OO, Gordeuk VR, Nick H.
    Br J Haematol; 2001 Dec 15; 115(4):918-23. PubMed ID: 11843826
    [Abstract] [Full Text] [Related]

  • 16. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
    Cappellini MD, Taher A.
    Expert Opin Pharmacother; 2008 Sep 15; 9(13):2391-402. PubMed ID: 18710363
    [Abstract] [Full Text] [Related]

  • 17. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
    Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A.
    Curr Med Chem; 2005 Sep 15; 12(23):2663-81. PubMed ID: 16305464
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.